Citation
García-Pérez, Javier, et al. "Longer Intervals Between SARS-CoV-2 Infection and mRNA-1273 Doses Improve the Neutralization of Different Variants of Concern." Journal of Medical Virology, vol. 95, no. 3, 2023, pp. e28679.
García-Pérez J, Bermejo M, Ramírez-García A, et al. Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern. J Med Virol. 2023;95(3):e28679.
García-Pérez, J., Bermejo, M., Ramírez-García, A., De La Torre-Tarazona, H. E., Cascajero, A., Castillo de la Osa, M., Jiménez, P., Aparicio Gómez, M., Calonge, E., Sancho-López, A., Payares-Herrera, C., Layunta Acero, R., Vicente-Izquierdo, L., Avendaño-Solá, C., Alcamí, J., Pérez-Olmeda, M., & Díez-Fuertes, F. (2023). Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern. Journal of Medical Virology, 95(3), e28679. https://doi.org/10.1002/jmv.28679
García-Pérez J, et al. Longer Intervals Between SARS-CoV-2 Infection and mRNA-1273 Doses Improve the Neutralization of Different Variants of Concern. J Med Virol. 2023;95(3):e28679. PubMed PMID: 36929737.
TY - JOUR
T1 - Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern.
AU - García-Pérez,Javier,
AU - Bermejo,Mercedes,
AU - Ramírez-García,Almudena,
AU - De La Torre-Tarazona,Humberto Erick,
AU - Cascajero,Almudena,
AU - Castillo de la Osa,María,
AU - Jiménez,Paloma,
AU - Aparicio Gómez,Marta,
AU - Calonge,Esther,
AU - Sancho-López,Aránzazu,
AU - Payares-Herrera,Concepción,
AU - Layunta Acero,Rocio,
AU - Vicente-Izquierdo,Laura,
AU - Avendaño-Solá,Cristina,
AU - Alcamí,José,
AU - Pérez-Olmeda,Mayte,
AU - Díez-Fuertes,Francisco,
PY - 2023/02/20/revised
PY - 2022/12/12/received
PY - 2023/03/14/accepted
PY - 2023/3/30/medline
PY - 2023/3/18/pubmed
PY - 2023/3/17/entrez
KW - Omicron
KW - hybrid immunity
KW - mRNA-1273
KW - neutralizing antibodies
KW - timing of vaccination
SP - e28679
EP - e28679
JF - Journal of medical virology
JO - J Med Virol
VL - 95
IS - 3
N2 - The humoral immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern elicited by vaccination was evaluated in COVID-19 recovered individuals (Rec) separated 1-3 months (Rec2m) or 4-12 months (Rec9m) postinfection and compared to the response in naïve participants. Antibody-mediated immune responses were assessed in 66 participants by three commercial immunoassays and a SARS-CoV-2 lentiviral-based pseudovirus neutralization assay. Immunoglobulin (Ig) levels against SARS-CoV-2 spike were lower in naïve participants after two doses than in Rec after a single dose (p < 0.05). After two doses in Rec, levels of total Ig to receptor-binding domain were significantly increased in Rec9m compared to Rec2m (p < 0.001). The neutralizing potency observed in Rec9m was consistently higher than in Rec2m against variants of concern (VOCs) Alpha, Beta, Delta, and BA.1 sublineage of Omicron with 2.2-2.8-fold increases. Increasing the interval between SARS-CoV-2 infection and the vaccination with messenger RNA-based vaccines to more than 3 months generates a more efficient heterologous humoral immune response against VOCs by allowing enough time to mount a strong recall memory B cell response.
SN - 1096-9071
UR - https://www.unboundmedicine.com/medline/citation/36929737/Longer_intervals_between_SARS_CoV_2_infection_and_mRNA_1273_doses_improve_the_neutralization_of_different_variants_of_concern_
DB - PRIME
DP - Unbound Medicine
ER -
